Current position

Ray Dalio’s Edwards Lifesciences Corp (EW) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Bridgewater Associates, LPVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2013Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares1.14MHighest verified quarter-end share count
Quarters reported37Verified quarters with shares above zero
What happened?

Bridgewater Associates, LP first reported Edwards Lifesciences Corp in Q3 2013. After an earlier exit, the position later appeared again in a verified filing. The reported position was increased and reduced across later filings. Bridgewater Associates, LP currently reports 275.28K shares. The latest verified filing showed: Bought 60.1% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Bought 60.1% more+103.36K shares · 275.28K shares reported after the change
Filing context

Quarter-end price $90.46 · Estimated holding basis $84.02

Q1 2026
Bought 124.0% more+95.16K shares · 171.92K shares reported after the change
Filing context

Quarter-end price $80.08 · Estimated holding basis $80.15

Q4 2025
Sold 57.4% of the position−103.55K shares · 76.76K shares remained
Filing context

Quarter-end price $85.25 · Estimated holding basis $80.24

Q3 2025
Sold 59.5% of the position−264.62K shares · 180.31K shares remained
Filing context

Quarter-end price $77.77 · Estimated holding basis $80.24

Q2 2025
Bought 611.6% more+382.40K shares · 444.92K shares reported after the change
Filing context

Quarter-end price $78.21 · Estimated holding basis $80.24

Q1 2025
Sold 42.3% of the position−45.76K shares · 62.52K shares remained
Filing context

Quarter-end price $72.48 · Estimated holding basis $92.69

Portfolio importance

How important is Edwards Lifesciences Corp in Bridgewater Associates, LP’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.1%Q2 2026
Current rank#166of 997 reported positions
Peak portfolio weight0.6%Q4 2021
Best historical rank#28Q1 2022
At peak importanceQ4 2021
EW
0.6%
Largest holding
5.2%
Cross-investor discovery

Who else owns Edwards Lifesciences Corp?

Also reported by 1 other tracked investor in their latest verified filings.

Joel GreenblattGotham Asset Management
EW0.0% of reported portfolio
Explore Edwards Lifesciences Corp across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$85.522026-09-14

Market context only; not an investor transaction price.

Latest filing quarter-end price$90.46Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$84.02Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Bridgewater Associates, LP’s Form 13F disclosures, not Ray Dalio’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.